Literature DB >> 23032060

Effects of type 2 diabetes and insulin on whole-body, splanchnic, and leg protein metabolism.

Kevin R Short1, Brian A Irving, Ananda Basu, C Michael Johnson, K Sreekumaran Nair, Rita Basu.   

Abstract

CONTEXT: Type 2 diabetes (T2D) is characterized by insulin resistance to glucose metabolism. Most studies suggest that protein metabolism is unaffected by T2D, but regional protein metabolism and response to multiple doses of insulin have not been examined.
OBJECTIVE: Our objective was to determine whether insulin regulation of splanchnic and leg protein metabolism are affected by T2D during hyperglycemia and graded insulin levels. DESIGN AND
SETTING: We conducted a cross-sectional study at an academic medical center. PARTICIPANTS: T2D and non-T2D adults were matched for age (62 yr) and body mass index (30 kg/m(2)).
INTERVENTIONS: Glucose was maintained at approximately 9 mmol/liter while insulin was infused at three progressively higher rates, achieving circulating concentrations of approximately 150, 350, and 700 pmol/liter, respectively. MAIN OUTCOME MEASURES: Protein kinetics were measured using labeled phenylalanine (Phe) and tyrosine (Tyr).
RESULTS: Whole-body protein breakdown and synthesis rates were higher in T2D but declined with increasing insulin in both groups. Leg Phe and Tyr appearance and disappearance and estimates of protein breakdown and synthesis, respectively, were higher in T2D but did not decline significantly with insulin, resulting in similar net balance between groups. Splanchnic response to insulin was blunted in T2D, shown by a smaller reduction in rates of disappearance and net balance of Phe and Tyr as insulin increased. Splanchnic conversion of Phe to Tyr was lower in T2D and less sensitive to insulin, whereas nonsplanchnic Phe to Tyr tended to be higher in T2D.
CONCLUSIONS: T2D results in higher whole-body, splanchnic, and leg protein turnover and blunts the insulin-mediated suppression of splanchnic protein anabolism under hyperglycemic, hyperinsulinemic conditions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23032060      PMCID: PMC3591680          DOI: 10.1210/jc.2012-2533

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  40 in total

1.  The kidney is an important site for in vivo phenylalanine-to-tyrosine conversion in adult humans: A metabolic role of the kidney.

Authors:  N Møller; S Meek; M Bigelow; J Andrews; K S Nair
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

2.  Gene expression profile in skeletal muscle of type 2 diabetes and the effect of insulin treatment.

Authors:  Raghavakaimal Sreekumar; Panagiotis Halvatsiotis; Jill Coenen Schimke; K Sreekumaran Nair
Journal:  Diabetes       Date:  2002-06       Impact factor: 9.461

3.  Tissue-specific regulation of mitochondrial and cytoplasmic protein synthesis rates by insulin.

Authors:  Y Boirie; K R Short; B Ahlman; M Charlton; K S Nair
Journal:  Diabetes       Date:  2001-12       Impact factor: 9.461

4.  Type 2 diabetes impairs splanchnic uptake of glucose but does not alter intestinal glucose absorption during enteral glucose feeding: additional evidence for a defect in hepatic glucokinase activity.

Authors:  A Basu; R Basu; P Shah; A Vella; C M Johnson; M Jensen; K S Nair; W F Schwenk; R A Rizza
Journal:  Diabetes       Date:  2001-06       Impact factor: 9.461

5.  Effects of type 2 diabetes on the ability of insulin and glucose to regulate splanchnic and muscle glucose metabolism: evidence for a defect in hepatic glucokinase activity.

Authors:  A Basu; R Basu; P Shah; A Vella; C M Johnson; K S Nair; M D Jensen; W F Schwenk; R A Rizza
Journal:  Diabetes       Date:  2000-02       Impact factor: 9.461

6.  Insulin effect on leucine kinetics in type 2 diabetes mellitus.

Authors:  P G Halvatsiotis; D Turk; A Alzaid; S Dinneen; R A Rizza; K S Nair
Journal:  Diabetes Nutr Metab       Date:  2002-06

7.  Leucine metabolism in type II diabetes mellitus.

Authors:  M A Staten; D E Matthews; D M Bier
Journal:  Diabetes       Date:  1986-11       Impact factor: 9.461

8.  Synthesis rate of muscle proteins, muscle functions, and amino acid kinetics in type 2 diabetes.

Authors:  Panagiotis Halvatsiotis; Kevin R Short; Maureen Bigelow; K Sreekumaran Nair
Journal:  Diabetes       Date:  2002-08       Impact factor: 9.461

9.  Effect of physiologic hyperinsulinemia on skeletal muscle protein synthesis and breakdown in man.

Authors:  R A Gelfand; E J Barrett
Journal:  J Clin Invest       Date:  1987-07       Impact factor: 14.808

10.  Impaired insulin-mediated skeletal muscle blood flow in patients with NIDDM.

Authors:  M Laakso; S V Edelman; G Brechtel; A D Baron
Journal:  Diabetes       Date:  1992-09       Impact factor: 9.461

View more
  3 in total

1.  Effect of insulin sensitizer therapy on amino acids and their metabolites.

Authors:  Brian A Irving; Rickey E Carter; Mattias Soop; Audrey Weymiller; Husnain Syed; Helen Karakelides; Sumit Bhagra; Kevin R Short; Laura Tatpati; Rocco Barazzoni; K Sreekumaran Nair
Journal:  Metabolism       Date:  2015-01-22       Impact factor: 8.694

2.  Liver alanine catabolism promotes skeletal muscle atrophy and hyperglycaemia in type 2 diabetes.

Authors:  Jürgen G Okun; Patricia M Rusu; Andrea Y Chan; Yuqin Wu; Yann W Yap; Thomas Sharkie; Jonas Schumacher; Kathrin V Schmidt; Katherine M Roberts-Thomson; Ryan D Russell; Annika Zota; Susanne Hille; Andreas Jungmann; Ludovico Maggi; Young Lee; Matthias Blüher; Stephan Herzig; Michelle A Keske; Mathias Heikenwalder; Oliver J Müller; Adam J Rose
Journal:  Nat Metab       Date:  2021-03-18

Review 3.  Muscle Loss in Chronic Liver Diseases: The Example of Nonalcoholic Liver Disease.

Authors:  Jean-Pascal De Bandt; Prasanthi Jegatheesan; Naouel Tennoune-El-Hafaia
Journal:  Nutrients       Date:  2018-09-01       Impact factor: 5.717

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.